WO2008070358A2 - Inhibiteurs de la sérine protéase de l'hépatite c et utilisations de ceux-ci - Google Patents

Inhibiteurs de la sérine protéase de l'hépatite c et utilisations de ceux-ci Download PDF

Info

Publication number
WO2008070358A2
WO2008070358A2 PCT/US2007/083034 US2007083034W WO2008070358A2 WO 2008070358 A2 WO2008070358 A2 WO 2008070358A2 US 2007083034 W US2007083034 W US 2007083034W WO 2008070358 A2 WO2008070358 A2 WO 2008070358A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
substituted
cycloalkyl
groups
heterocyclyl
Prior art date
Application number
PCT/US2007/083034
Other languages
English (en)
Other versions
WO2008070358A3 (fr
Inventor
David Alan Campbell
Michael E. Hepperle
David T. Winn
Juan Manuel Betancort
Original Assignee
Phenomix Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenomix Corporation filed Critical Phenomix Corporation
Publication of WO2008070358A2 publication Critical patent/WO2008070358A2/fr
Publication of WO2008070358A3 publication Critical patent/WO2008070358A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N

Definitions

  • the present invention relates to novel compounds that are useful as protease inhibitors, particularly as inhibitors of serine proteases, and more particularly as inhibitors of the NS3 serine protease from hepatitis C virus.
  • the compounds find utility as antiviral agents, especially for treatment of hepatitis C virus infections.
  • Hepatitis C virus is the causative agent for hepatitis C, a chronic infection characterized by jaundice, fatigue, abdominal pain, loss of appetite, nausea, and darkening of the urine.
  • HCV belonging to the hepacivirus genus of the Flaviviriae family, is an enveloped, single-stranded positive-sense RNA-containing virus.
  • the long-term effects of hepatitis C infection as a percentage of infected subjects include chronic infection (55-85%), chronic liver disease (70%), and death (1-5%).
  • HCV is the leading indication for liver transplant. In chronic infection, there usually presents progressively worsening liver inflammation, which often leads to more severe disease states such as cirrhosis and hepatocellular carcinoma.
  • the HCV genome (Choo et al., Science 1989, 244, 359-362; Simmonds et al., Hepatology 1995, 21, 570-583) is a highly variable sequence exemplified by GenBank accession NC_004102 as a 9646 base single-stranded RNA comprising the following constituents at the parenthetically indicated positions: 5' NTR (i.e., non-transcribed region) (1-341); core protein (i.e., viral capsid protein involved in diverse processes including viral morphogenesis or regulation of host gene expression) (342-914); El protein (i.e., viral envelope) (915-1490); E2 protein (i.e., viral envelope) (1491-2579); p7 protein (2580- 2768); NS2 protein (i.e., non-structural protein 2) (2769-3419); NS3 protease (3420-5312); NS4a protein (5313-5474); NS4b protein (5475-6257);
  • the NS3 (i.e., non-structural protein 3) protein of HCV exhibits serine protease activity, the N-terminus of which is produced by the action of aNS2- NS3 metal-dependent protease, and the C-terminus of which is produced by auto-proteolysis.
  • the HCV NS3 serine protease and its associated cofactor, NS4a process all of the other non-structural viral proteins of HCV. Accordingly, the HCV NS3 protease is essential for viral replication.
  • An embodiment according to the present invention provides compounds of formula (I) that are adapted to inhibit the viral protease NS 3 of the Hepatitis C Virus (HCV).
  • the compounds of formula (I) are adapted to bind to, and thus block the action of, an HCV-encoded protease enzyme that is required by the virus for the production of intact, mature, functional viral proteins from the viral polyprotein as translated from the viral RNA, and therefore for the formation of infectious particles, and ultimately for viral replication.
  • the compounds of the invention can be considered as mimics or analogs of the peptide domain immediately N-terminal of the substrate site where the viral protease cleaves its native substrate viral polyprotein.
  • Another embodiment provides a method of treatment of a patient for whom inhibition of Hepatitis C protease is medically indicated, or a patient infected with Hepatitis C, using a compound of formula (I).
  • Another embodiment provides methods of synthesis of the compounds of formula (I), and further embodiments provide pharmaceutical compositions and combinations including a compound of formula (I), useful for the treatment of Hepatitis C. Accordingly, an embodiment of the present invention is directed to a compound of formula (I):
  • R c at each occurrence is independently H, or a substituted or unsubstituted alkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, or heteroarylalkyl; wherein any carbon atom can be substituted with a J group; or two R° groups together with a nitrogen atom to which they are bound form together with the nitrogen atom a 5-11 membered mono- or bicyclic heterocyclic ring system that is unsubstituted or is substituted with 1 -3 J groups;
  • A is
  • a wavy line signifies a point of attachment
  • m is 1 or 2
  • X is a bond, C(R 4 ) 2 , N(R 5 ), O or S;
  • Y is C(O), S(O) or S(O) 2 ;
  • Z is alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, OR 5 , or N(R 5 ) 2 , wherein any carbon atom is unsubstituted or is substituted with J;
  • R 1 and R la are independently H, or a substituted or unsubstituted alkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl; wherein any alkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl
  • R 2 and R 2a are independently H, or a substituted or unsubstituted alkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl; wherein any alkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl can be unsubstituted or substituted with 1-3 J groups;
  • R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, cycloalkenyl, cycloalkenylalkyl, cycloalkenylalkenyl, or cycloalkenylalkynyl; wherein any R 3 can be unsubstituted or substituted with 1-3 J groups; n is 1, 2 or 3; R 4 is at each occurrence independently H, or a substituted or unsubstituted alkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylalkyl, cycloalkylalkenyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, heteroarylalky
  • R 5 is H, or unsubstituted or substituted alkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, or heteroarylalkyl, wherein any alkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, or heteroarylalkyl group can be substituted with 0-3 J groups; or two R 5 groups together with a nitrogen atom to which they are attached form together with the nitrogen atom a C 3 -C 8 hetero
  • J is halogen, OR', OC(O)N(R') 2 , NO 2 , CN, CF 3 , OCF 3 , R', N(R) 2 , SR, SOR', SO 2 R, SO 2 N(R) 2 , SO 3 R, C(O)R', C(O)C(O)R', C(O)CH 2 C(O)R, C(S)R, C(O)OR', OC(O)R 1 , C(0)N(R') 2 , 0C(0)N(R') 2 , C(S)N(R') 2 , (CH 2 ) 0-
  • W is C(R 10 ) 2 , O, S, NH, or NR';
  • V is a bond, C( R 10 ) 2 , C(O), S(O), or S(O) 2 ; provided that when W is C(R I0 ) 2 , V is not also C(R 10 ) 2 ;
  • R 10 is independently at each occurrence H, or alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl, wherein any carbon atom can be substituted with J; or two R 10 groups together with a carbon atom to which they are bound form a 3-8 membered cycloalkyl, which can be unsubstituted or substituted with 1 -3 J, wherein the 3-8 membered cycloalkyl can contain 1-3 heteroatoms selected from the group consisting of O, NH, NR', S, S(O), or S(O) 2 , wherein the 3-8 membered cycloalky
  • K is a bond, O, S, C(O), S(O), S(O) 2 , S(O)(NR 10 ), or N(R 10 );
  • T is R 11 , alkyl-R 11 , alkenyl-R 11 , alkynyl-R 11 , OR 11 , N(R 11 ) 2 , C(O) R 11 , or
  • R 11 is independently H, or alkyl, aryl, aralkyl, alkoxy, cycloalkyl, cycloalkylidenyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkylidenyl, or heteroaryl, wherein any R 11 except hydrogen is substituted with 0-3 J groups, or a first R 1 ] and a second R 11 together with a nitrogen atom to which they are bound form together with the nitrogen atom a mono- or bicyclic heterocyclyl ring system substituted with 0-3 J groups.
  • Z is
  • R 12 , R 13 , R 14 , R 15 , R 18 , and R 19 are independently H, F, or a substituted or unsubstituted alkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylalkyl, cycloalkylalkenyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or heteroarylalkenyl group; or R 12 and R 13 or R 14 and R 15 or R 18 and R 19 , together with a carbon atom to which they are attached, form a C 3-8 cycloalkyl group; and R 16 and R 17 are independently H or a substituted or unsubstituted alkyl,
  • R 12 , R 13 , R 14 and R 15 are independently H, F, or a substituted or unsubstituted alkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylalkyl, cycloalkylalkenyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or heteroarylalkenyl group; or R 12 and R 13 together with a carbon atom to which they are attached or R 14 and R 15 together with a carbon atom to which they are attached form together with the carbon atom a C 3-8 cycloalkyl group which can be unsubstituted or substituted with 1-3 J groups; R >2 z 0 ⁇ , r R>21 , R >22 , and R
  • the invention further provides a pharmaceutical composition comprising a compound of formula (I) and a suitable excipient.
  • the invention further provides a pharmaceutical combination comprising a compound of formula (I) in a therapeutically effective amount and a second medicament in a therapeutically effective amount.
  • the combination can further comprise a third medicament in a therapeutically effective amount.
  • a pharmaceutical combination of the invention may be formulated as a pharmaceutical composition of the invention.
  • the present invention further provides a method of treatment of a HCV infection in a patient in need thereof, or in a patient when inhibition of an HCV viral protease is medically indicated, comprising administering a therapeutically effective amount of a compound of formula (I) to the patient, or administering a pharmaceutical combination of the invention comprising a compound of formula (I) and second medicament, and, optionally, a third medicament, all in therapeutically effective doses, to the patient.
  • HCV NS3 serine protease denotes all active forms of the serine protease encoded by the NS3 region of the hepatitis C virus, including all combinations thereof with other proteins in either covalent or noncovalent association.
  • other proteins in this context include without limitation the protein encoded by the NS4a region of the hepatitis C virus. Accordingly, the terms “NS3/4a” and “NS3/4a protease” denote the NS3 protease in combination with the HCV NS4a protein.
  • other type(s) of therapeutic agents refers to one or more antiviral agents (other than HCV NS3 serine protease inhibitors of the invention).
  • Subject as used herein, includes mammals such as humans, non-human primates, rats, mice, dogs, cats, horses, cows and pigs.
  • treatment is defined as the management and care of a patient for the purpose of combating the disease, condition, or disorder and includes administering a compound of the present invention to prevent the onset of the symptoms or complications, or alleviating the symptoms or complications, or eliminating the disease, condition, or disorder.
  • Treating within the context of the instant invention means an alleviation of symptoms associated with a disorder or disease, or inhibition of further progression or worsening of those symptoms, or prevention or prophylaxis of the disease or disorder.
  • treating a hepatitis C viral infection includes slowing, halting or reversing the growth of the virus and/or the control, alleviation or prevention of symptoms of the infection.
  • an "effective amount” or a “therapeutically effective amount” of a compound of the invention refers to an amount of the compound that alleviates, in whole or in part, symptoms associated with the disorder or condition, or halts or slows further progression or worsening of those symptoms, or prevents or provides prophylaxis for the disorder or condition.
  • a “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result by inhibition of HCV NS3 serine protease activity.
  • a therapeutically effective amount is also one in which any toxic or detrimental effects of compounds of the invention are outweighed by the therapeutically beneficial effects.
  • a therapeutically effective amount of a HCV NS 3 serine protease inhibitor of the invention is an amount sufficient to control HCV viral infection. All chiral, diastereomeric, racemic forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated.
  • amino protecting group or "N-protected” as used herein refers to those groups intended to protect an amino group against undesirable reactions during synthetic procedures and which can later be removed to reveal the amine. Commonly used amino protecting groups are disclosed in Protective Groups in Organic Synthesis, Greene, T.W.; Wuts, P. G. M., John Wiley & Sons, New York, NY, (3rd Edition, 1999), incorporated herein by reference.
  • Amino protecting groups include acyl groups such as formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, o-nitrophenoxyacetyl, ⁇ -chlorobutyryl, benzoyl, 4- chlorobenzoyl, 4-bromobenzoyl, 4-nitrobenzoyl, and the like; sulfonyl groups such as benzenesulfonyl, p-toluenesulfonyl and the like; acyloxy groups (which form urethanes with the protected amine) such as benzyloxycarbonyl (Cbz), p- chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p- nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbon
  • Amine protecting groups also include cyclic amino protecting groups such as phthaloyl and dithiosuccinimidyl, which incorporate the amino nitrogen into a heterocycle.
  • amino protecting groups include formyl, acetyl, benzoyl, pivaloyl, t-butylacetyl, phenylsulfonyl, Alloc, Teoc, benzyl, Fmoc, Boc and Cbz. It is well within the skill of the ordinary artisan to select and use the appropriate amino protecting group for the synthetic task at hand.
  • substituted refers to an organic group as defined herein in which one or more bonds to a hydrogen atom contained therein are replaced by a bond to non-hydrogen or non-carbon atoms such as, but not limited to, a halogen (i.e., F, Cl, Br, and I); an oxygen atom in groups such as hydroxyl groups, alkoxy groups, aryloxy groups, aralkyloxy groups; a sulfur atom in groups such as thiol groups, alkyl and aryl sulfide groups, sulfoxide groups, sulfone groups, sulfonyl groups, and sulfonamide groups; a nitrogen atom in groups such as amines, hydroxylamines, N-oxides, hydrazides, azides, and enamines; and other heteroatoms in various other groups.
  • a halogen i.e., F, Cl, Br, and I
  • an oxygen atom in groups such as hydroxyl groups, alk
  • Substituted alkyl, alkenyl, alkynyl, cycloalkyl, and cycloalkenyl groups as well as other substituted groups also include groups in which one or more bonds to a carbon(s) or hydrogen(s) atom are replaced by one or more bonds, including double or triple bonds, to a heteroatom such as, but not limited to, oxygen in carbonyl (oxo), carboxyl, ester, amide, imide, urethane, and urea groups; and nitrogen in imines, hydroxyimines, oximes, hydrazones, amidines, guanidines, and nitriles.
  • Substituted ring groups such as substituted aryl, heterocyclyl and heteroaryl groups also include rings and fused ring systems in which a bond to a hydrogen atom is replaced with a bond to a carbon atom. Therefore, substituted aryl, heterocyclyl and heteroaryl groups may also be substituted with alkyl, alkenyl, and alkynyl groups as defined herein.
  • Alkyl groups include straight chain and branched alkyl groups and cycloalkyl groups having from 1 to about 20 carbon atoms, and typically from 1 to 12 carbons or, in some embodiments, from 1 to 8 carbon atoms.
  • straight chain alkyl groups include those with from 1 to 8 carbon atoms such as methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, and n-octyl groups.
  • branched alkyl groups include, but are not limited to, isopropyl, iso-butyl, sec-butyl, t-butyl, neopentyl, isopentyl, and 2,2-dimethylpropyl groups.
  • Representative substituted alkyl groups may be substituted one or more times with any of the groups listed above, for example, amino, hydroxy, cyano, carboxy, nitro, thio, alkoxy, and halogen groups.
  • Cycloalkyl groups are cyclic alkyl groups such as, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups.
  • the cycloalkyl group has 3 to 8 ring members, whereas in other embodiments the number of ring carbon atoms range from 3 to 5, 6, or 7.
  • Cycloalkyl groups further include polycyclic cycloalkyl groups such as, but not limited to, norbornyl, adamantyl, bornyl, camphenyl, isocamphenyl, and carenyl groups, and fused rings such as, but not limited to, decalinyl, and the like. Cycloalkyl groups also include rings that are substituted with straight or branched chain alkyl groups as defined above.
  • Representative substituted cycloalkyl groups may be mono-substituted or substituted more than once, such as, but not limited to, 2,2-, 2,3-, 2,4- 2,5- or 2,6-disubstituted cyclohexyl groups or mono-, di- or tri-substituted norbornyl or cycloheptyl groups, which may be substituted with, for example, amino, hydroxy, cyano, carboxy, nitro, thio, alkoxy, and halogen groups.
  • cycloalkenyl alone or in combination denotes a cyclic alkenyl group.
  • carbocyclic and “carbocycle” denote a ring structure wherein the atoms of the ring are carbon.
  • the carbocycle has 3 to 8 ring members, whereas in other embodiments the number of ring carbon atoms is 4, 5, 6, or 7.
  • the carbocyclic ring may be substituted with as many as N-I substituents wherein N is the size of the carbocyclic ring with for example, amino, hydroxy, cyano, carboxy, nitro, thio, alkoxy, and halogen groups.
  • (Cycloalkyl)alkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of the alkyl group is replaced with a bond to a cycloalkyl group as defined above.
  • Alkenyl groups include straight and branched chain and cyclic alkyl groups as defined above, except that at least one double bond exists between two carbon atoms.
  • alkenyl groups have from 2 to about 20 carbon atoms, and typically from 2 to 12 carbons or, in some embodiments, from 2 to 8 carbon atoms.
  • Cycloalkenyl groups include cycloalkyl groups having at least one double bond between 2 carbons.
  • cycloalkenyl groups include but are not limited to cyclohexenyl, cyclopentenyl, and cyclohexadienyl groups.
  • (Cycloalkenyl)alkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of the alkyl group is replaced with a bond to a cycloalkenyl group as defined above.
  • Alkynyl groups include straight and branched chain alkyl groups, except that at least one triple bond exists between two carbon atoms. Thus, alkynyl groups have from 2 to about 20 carbon atoms, and typically from 2 to 12 carbons or, in some embodiments, from 2 to 8 carbon atoms.
  • Examples include, but are not limited to -CkCH, -C ⁇ C(CH3), -C ⁇ C(CH2CH3), -CH2C ⁇ CH, -CH2C ⁇ C(CH3), and -CH2C ⁇ C(CH2CH3) among others.
  • Aryl groups are cyclic aromatic hydrocarbons that do not contain heteroatoms.
  • aryl groups include, but are not limited to, phenyl, azulenyl, heptalenyl, biphenyl, indacenyl, fluorenyl, phenanthrenyl, triphenylenyl, pyrenyl, naphthacenyl, chrysenyl, biphenylenyl, anthracenyl, and naphthyl groups.
  • aryl groups contain 6-14 carbons in the ring portions of the groups.
  • aryl groups includes groups containing fused rings, such as fused aromatic-aliphatic ring systems (e.g., indanyl, tetrahydronaphthyl, and the like), it does not include aryl groups that have other groups, such as alkyl or halogen groups, bonded to one of the ring members. Rather, groups such as tolyl are referred to as substituted aryl groups.
  • Representative substituted aryl groups may be mono-substituted or substituted more than once, such as, but not limited to, 2-, 3-, 4-, 5-, or 6-substituted phenyl or naphthyl groups, which may be substituted with groups such as those listed above.
  • Aralkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to an aryl group as defined above.
  • Representative aralkyl groups include benzyl and phenylethyl groups and fused (cycloalkylaryl)alkyl groups such as 4-ethyl-indanyl.
  • Aralkenyl group are alkenyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to an aryl group as defined above.
  • Heterocyclyl groups include aromatic and non-aromatic ring compounds containing 3 or more ring members, of which, one or more is a heteroatom such as, but not limited to, N, O, and S. In some embodiments, heterocyclyl groups include 3 to 20 ring members, whereas other such groups have 3 to 15 ring members.
  • the phrase "heterocyclyl group” includes fused ring species including those comprising fused aromatic and non-aromatic groups.
  • the phrase also includes polycyclic ring systems containing a heteroatom such as, but not limited to, quinuclidyl.
  • the phrase does not include heterocyclyl groups that have other groups, such as alkyl or halogen groups, bonded to one of the ring members. Rather, these are referred to as "substituted heterocyclyl groups”.
  • Heterocyclyl groups include, but are not limited to, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridinyl, thiophenyl, benzothiophenyl, benzofuranyl, dihydrobenzofuranyl, indolyl, dihydroindolyl, azaindolyl, indazolyl, benzimidazolyl, azabenzimidazolyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, imidazopyridinyl, isoxazolopyridinyl, thianaphthalenyl, purinyl, xanthinyl, adeninyl, guaninyl, quinolinyl, isoquino
  • Representative substituted heterocyclyl groups may be mono-substituted or substituted more than once, such as, but not limited to, piperidinyl or quinolinyl groups, which are 2-, 3-, 4-, 5-, or 6-substituted, or disubstituted with groups such as those listed above.
  • Heteroaryl groups are aromatic ring compounds containing 5 or more ring members, of which, one or more is a heteroatom such as, but not limited to, N, O, and S.
  • Heteroaryl groups include, but are not limited to, groups such as pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridinyl, thiophenyl, benzothiophenyl, benzofuranyl, indolyl, azaindolyl, indazolyl, benzimidazolyl, azabenzimidazolyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, imidazopyridinyl, isoxazolopyridinyl, thianaphthalenyl, purinyl, xanthinyl, adeninyl, guaninyl, quinolin
  • heteroaryl groups includes fused ring compounds such as indolyl and 2,3-dihydro indolyl, the phrase does not include heteroaryl groups that have other groups bonded to one of the ring members, such as alkyl groups. Rather, heteroaryl groups with such substitution are referred to as "substituted heteroaryl groups”. Representative substituted heteroaryl groups may be substituted one or more times with groups such as those listed above.
  • aryl and heteroaryl groups include but are not limited to phenyl, biphenyl, indenyl, naphthyl (1-naphthyl, 2-naphthyl), N- hydroxytetrazolyl, N-hydroxytriazolyl, N-hydroxyimidazolyl, anthracenyl ( 1 - anthracenyl, 2-anthracenyl, 3 -anthracenyl), thiophenyl (2-thienyl, 3-thienyl), furyl (2-furyl, 3-furyl) , indolyl, oxadiazolyl, isoxazolyl, quinazolinyl, fluorenyl, xanthenyl, isoindanyl, benzhydryl, acridinyl, thiazolyl, pyrrolyl (2-pyrrolyl), pyrazolyl (3 -pyrazolyl), imidazolyl (1-imid
  • Heterocyclylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a heterocyclyl group as defined above.
  • Representative heterocyclyl alkyl groups include, but are not limited to, furan-2-yl methyl, furan-3-yl methyl, pyridine-3- yl methyl, tetrahydrofuran-2-yl ethyl, and indol-2-yl propyl.
  • Heteroarylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a heteroaryl group as defined above.
  • alkoxy refers to an oxygen atom connected to an alkyl group as defined above.
  • linear alkoxy groups include but are not limited to methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, and the like.
  • branched alkoxy include but are not limited to isopropoxy, sec- butoxy, tert-butoxy, isopentyloxy, isohexyloxy, and the like.
  • cyclic alkoxy include but are not limited to cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.
  • aryloxy and arylalkoxy refer to, respectively, an aryl group bonded to an oxygen atom and an aralkyl group bonded to the oxygen atom at the alkyl. Examples include but are not limited to phenoxy, naphthyloxy, and benzyloxy.
  • amine (or “amino”) includes primary, secondary, and tertiary amines having, e.g., the formula -NR 2 . Amines include but are not limited to -NH 2 , alkylamines, dialkylamines, arylamines, alkylarylamines, diarylamines, aralkylamines, heterocyclylamines and the like.
  • amide includes C- and N-amide groups, i.e., -C(O)NR 2 , and -NRC(O)R groups, respectively.
  • Amide groups therefore include but are not limited to carbamoyl groups (-C(O)NH 2 ) and formamide groups (-NHC(O)H).
  • urethane (or “carbamyl”) includes N- and O-urethane groups, i.e., -NRC(O)OR and -OC(O)NR 2 groups, respectively.
  • sulfonamide (or “sulfonamido”) includes S- and N- sulfonamide groups, i.e., -SO 2 NR 2 and -NRSO 2 R groups, respectively. Sulfonamide groups therefore include but are not limited to sulfamoyl groups (- SO 2 NH 2 ).
  • amidine or “amidino” includes groups of the formula -C(NR)NR 2 .
  • an amidino group is -C(NH)NH 2 .
  • guanidine or "guanidino” includes groups of the formula -NRC(NR)NR 2 . Typically, a guanidino group is -NHC(NH)NH 2 .
  • a guanidino group is -NHC(NH)NH 2 .
  • X is described as selected from the group consisting of bromine, chlorine, and iodine, claims for X being bromine and claims for X being bromine and chlorine are fully described.
  • R c at each occurrence is independently H, or a substituted or unsubstituted alkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, or heteroarylalkyl; wherein any carbon atom can be substituted with a J group; or two R c groups together with a nitrogen atom to which they are bound form together with the nitrogen atom a 5-11 membered mono- or bicyclic heterocyclic ring system that is unsubstituted or is substituted with 1-3 J groups;
  • a wavy line signifies a point of attachment
  • m is 1 or 2
  • X is a bond, C(R 4 ) 2 , N(R 5 ), O or S;
  • Y is C(O), S(O) or S(O) 2 ;
  • Z is alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, OR 5 , or N(R 5 ) 2 , wherein any carbon atom is unsubstituted or is substituted with J;
  • R 1 and R la are independently H, or a substituted or unsubstituted alkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl; wherein any alkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl can unsubstituted or substituted with 1-3 J groups;
  • R 2 and R 2a are independently H, or a substituted or unsubstituted alkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl; wherein any alkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl can be unsubstituted or substituted with 1-3 J groups;
  • R is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, cycloalkenyl, cycloalkenylalkyl, cycloalkenylalkenyl, or cycloalkenylalkynyl; wherein any R 3 can be unsubstituted or substituted with 1-3 J groups; n is 1, 2 or 3;
  • R 4 is at each occurrence independently H, or a substituted or unsubstituted alkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylalkyl, cycloalkylalkenyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or heteroarylalkenyl, or two R 4 groups together with a carbon atom to which they are attached form together with the carbon atom a C 3- C 8 cycloalkyl group; wherein any carbon atom can be substituted with J;
  • R 5 is H, or unsubstituted or substituted alkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cyclo
  • J is halogen, OR', 0C(0)N(R') 2 , NO 2 , CN, CF 3 , OCF 3 , R', N(R) 2 , SR 1 , SOR 1 , SO 2 R 1 , SO 2 N(R) 2 , SO 3 R, C(O)R 1 , C(O)C(O)R, C(O)CH 2 C(O)R, C(S)R 1 , C(O)OR 1 , OC(O)R 1 , C(0)N(R') 2 , OC(O)N(R) 2 , C(S)N(RO 2 , (CH 2 )o- 2N(If)C(O)R 1 , N(R)N(ROC(O)R', N(R')N(R)C(0)0R', N(RON(ROCON(RO 2 , N(R)SO 2 R 1 , N(ROSO 2 N(RO 2 , N(R)C(O)OR,
  • W is C(R 10 ) 2 , O, S, NH, or NR 1 ;
  • V is a bond, C( R 10 ) 2 , C(O), S(O), or S(O) 2 ; provided that when W is C(R 10 ) 2 , V is not also C(R 10 ) 2 ;
  • R 10 is independently at each occurrence H, or alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl, wherein any carbon atom can be substituted with J; or two R 10 groups together with a carbon atom to which they are bound form a 3-8 membered cycloalkyl, which can be unsubstituted or substituted with 1-3 J, wherein the 3-8 membered cycloalkyl can contain 1-3 heteroatoms selected from the group consisting of O, NH, NR', S, S(O), or S(O) 2 , wherein the 3-8 membered cycloalkyl can
  • K is a bond, O, S, C(O), S(O), S(O) 2 , S(O)(NR 10 ), or N(R 10 );
  • R 11 is independently H, or alkyl, aryl, aralkyl, alkoxy, cycloalkyl, cycloalkylidenyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkylidenyl, or heteroaryl, wherein any R 11 except hydrogen is substituted with 0-3 J groups, or a first R 1 ' and a second R 1 ! together with a nitrogen atom to which they are bound form together with the nitrogen atom a mono- or bicyclic heterocyclyl ring system substituted with 0-3 J groups.
  • a compound of the invention can be a compound of formula (I) wherein Q is , wherein R c is unsubstituted or substituted cyclopropyl or aryl.
  • R c can be cyclopropyl, or R c can be phenyl.
  • a compound of the invention can be a compound of formula (I) wherein R 3 is alkenyl.
  • R 3 can be C 2 H 3 (ethenyl).
  • a compound of the invention can be a compound of formula (I) wherein X is O. More specifically, a compound of the invention can be a compound of formula (I) wherein Y is C(O).
  • a compound of the invention can be a compound of formula (I) wherein Z is heterocyclyl or heteroaryl.
  • Z can be
  • R 12 , R 13 , R 14 , R 15 , R 18 , and R 19 are independently H, F, or a substituted or unsubstituted alkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylalkyl, cycloalkylalkenyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or heteroarylalkenyl group; or R 12 and R 13 or R 14 and R 15 or R 18 and R 19 , together with the carbon to which they are attached, form a C 3-8 cycloalkyl group; and R 16 and R 17 are independently H or a substituted or unsubstituted alkyl, cyclo
  • a compound of the invention can be a compound of formula (I) wherein Z is
  • a compound of formula (I) can also comprise a compound wherein Z is
  • a compound of the invention can be a compound of formula (I) wherein W is CH 2 or NH.
  • a compound of the invention can be a compound of formula (I) wherein V is C(O).
  • a compound of the invention can be a compound of formula (I) wherein K is O.
  • a compound of the invention can be a compound of formula (I) wherein T is R 11 or alkyl-R 11 .
  • a compound of the invention can be a compound of formula (I) wherein T is /-butyl, neopentyl, or cyclopentyl. More specifically, a compound of the invention can be a compound of formula (I) wherein R 2 is cycloalkyl.
  • a compound of the invention can be a compound of formula (I) wherein R 2 is cyclohexyl and R 2a is H.
  • a compound of the invention can be a compound of formula (I) wherein the stereochemistry of the compound is:
  • a compound of the invention can be a compound of formula (I) wherein the stereochemistry of the compound is:
  • a compound of the invention can be a compound of formula (I) wherein the compound is:
  • a compound of the invention can be a compound of formula (I) wherein the compound is:
  • a compound of the invention can be a compound of formula (I) wherein the compound is:
  • An embodiment according to the invention provides a method for synthesis of a compound of formula (I):
  • the conditions effective to bring about formation of the compound of formula (I) include
  • An embodiment according to the invention further provides a method of synthesis of a compound of formula (IA):
  • An embodiment of the invention further comprises preparing a compound of formula (IA):
  • Q comprises: S O2N(R0)2 R' wherein a wavy line signifies a point of attachment, the method comprising contacting a compound of formula (IA), wherein Q is CO 2 H, with HN(R C ) 2 , HN(R C )SO 2 R C , or HN(R C )SO 2 N(R C ) 2 respectively under conditions effective to provide the compound of formula (IA) wherein Q comprises:
  • the invention provides methods of inhibiting HCV NS3 protease.
  • the methods include contacting the hepatitis C viral serine protease with a compound as described herein.
  • the methods of inhibiting HCV NS3 protease include administering a compound as described herein to a subject infected with hepatitis C virus.
  • the invention provides methods for treating hepatitis C viral infection.
  • the methods include administering to a subject in need of such treatment an effective amount of a compound of the invention as described herein.
  • a compound can refer to a single compound or a plurality of compounds.
  • the methods for treating hepatitis C viral infection include administering to a subject in need of such treatment an effective amount of a composition comprising a compound of the invention and a pharmaceutically acceptable carrier.
  • the invention provides methods for treating hepatitis C viral infection comprising administering to a subject in need of such treatment an effective amount of a compound of the invention in combination with another anti-viral agent.
  • anti-viral agent denotes a compound which interferes with any stage of the viral life cycle to slow or prevent HCV reproduction.
  • Representative anti-viral agents include, without limitation, NS3 protease inhibitors, INTRON-A, (interferon alfa-2b available from Schering Corporation, Kenilworth, N.J.), PEG-INTRON (peginteferon alfa-2b, available from Schering Co ⁇ oration, Kenilworth, N.J.), ROFERON-A (recombinant interferon alfa-2a available Hoffmann-La Roche, Nutley, N.J.), PEGASYS (peginterferon alfa-2a available Hoffmann-La Roche, Nutley, N.J.), INFERGEN A (Schering Plough, inteferon-alpha 2B+Ribavirin), WELLFERON (interferon alpha-nl), nucleoside analogues, IRES inhibitors, NS5b inhibitors, El inhibitors, E2 inhibitors, IMPDH inhibitors, NS5 polymerase inhibitors and/or NTPase/helicase inhibitors.
  • the methods of treating HCV infection include administering to a subject in need of such treatment an effective amount of a compound of the invention in combination with another NS3 protease inhibitor.
  • NS3 protease inhibitors which can be administered in combination with compounds of the present invention include, without limitation, VX950 and BILN2061 (Lin C, Lin K, Luong Y, Rao BG, Wei YY, Brennan DL, Fulghum JR, Hsiao HM, Ma S, Maxwell JP, Cottrell KM, Perni RB, Gates CA, Kwong AD, "In Vitro
  • Still other antiviral agents that may be used in conjunction with inventive compounds for the treatment of HCV infection include, but are not limited to, ribavirin (l-beta-D-ribofuranosyl-lH-l,2,4-triazole-3-carboxamide, available from ICN Pharmaceuticals, Inc., Costa Mesa, Calif; described in the Merck Index, entry 8365, Twelfth Edition); REBETROL.RTM. (Schering Corporation, Kenilworth, N.J.), COPEGASUS. RTM. (Hoffmann-La Roche, Nutley, N.J.); BEREFOR.RTM.
  • interleukin 12 (Davis, G. L. et al., "Future Options for the Management of Hepatitis C.” Seminars in Liver Disease, 19, pp. 103-112 (1999); and compounds that enhance the development of type 1 helper T cell response (Davis et al., "Future Options for the Management of hepatitis C.” Seminars in Liver Disease, 19, pp. 103-112 (1999)).
  • compounds that stimulate the synthesis of interferon in cells (Tazulakhova, E. B. et al., "Russian Experience in Screening, analysis, and Clinical Application of Novel Interferon Inducers" J. Interferon Cytokine Res., 21 pp.
  • the invention provides a method for treating hepatitis C viral infection, comprising administering to a subject in need of such treatment an effective amount of a compound of the invention in combination with an antiproliferative agent.
  • antiproliferative agent denotes a compound which inhibits cellular proliferation. Cellular proliferation can occur, for example without limitation, during carcinogenesis, metastasis, and immune responses.
  • Representative antiproliferative agents include, without limitation, 5-fluorouracil, daunomycin, mitomycin, bleomycin, dexamethasone, methotrexate, cytarabine, mercaptopurine.
  • the invention provides a method for treating hepatitis C viral infection, comprising administering to a subject in need of such treatment an effective amount of a compound of the invention in combination with an immune modulator.
  • immune modulator denotes a compound or composition comprising a plurality of compounds which changes any aspect of the functioning of the immune system.
  • immune modulator includes without limitation anti-inflammatory agents and immune suppressants.
  • Representative immune modulator include without limitation steroids, non-steroidal antiinflammatories, COX2 inhibitors, anti- TNF compounds, anti-IL-1 compounds, methotrexate, leflunomide, cyclosporin, FK506 and combinations of any two or more thereof.
  • Representative steroids in this context include without limitation prednisone, prednisolone, and dexamethasone.
  • Representative non-steroidal anti-inflammatory agents in this context include without limitation ibuprofen, naproxen, diclofenac, and indomethacin.
  • Representative COX2 inhibitors in this context include without limitation rofecoxib and celecoxib.
  • Representative Anti-TNF compounds in this context include without limitation enbrel, infliximab, and adalumimab.
  • Representative anti-IL-1 compounds in this context include without limitation anakinra.
  • Representative immune suppressants include without limitation cyclosporin and FK506.
  • Compounds of the invention include mixtures of stereoisomers such as mixtures of diastereomers and/or enantiomers.
  • the compound e.g. of Formula I, is 90 weight percent (wt %) or greater of a single diastereomer of enantiomer.
  • the compound is 92, 94, 96, 98 or even 99 wt % or more of a single diastereomer or single enantiomer.
  • a variety of uses of the invention compounds are possible along the lines of the various methods of treating a subject as described above.
  • Exemplary uses of the invention methods include, without limitation, use of a compound of the invention in a medicament or for the manufacture of a medicament for treating a condition that is regulated or normalized via inhibition of the HCV NS3 serine protease.
  • Fluorescence resonance energy transfer (FRET; see e.g., Heim et al., (1996) Curr. Biol. 6:178-182; Mitra et al., (1996) Gene 173:13-17; and Selvin et al., (1995) Meth. Enzymol. 246:300-345) is an extremely sensitive method for detecting energy transfer between two fluorophoric probes.
  • probes are given the designations "donor” and "acceptor” depending on the relative positions of the maxima in the absorption and emission spectra characterizing the probes. If the emission spectrum of the acceptor overlaps the absorption spectrum of the donor, energy transfer can occur.
  • FRET measurements correlate with distance. For example, when the probes are in proximity, such as when the probes are attached to the N- and C- termini of a peptide substrate, and the sample is illuminated in a spectrofluorometer, resonance energy can be transferred from one excited probe to the other resulting in observable signal. Upon scission of the peptide linking the probes, the average distance between probes increases such that energy transfer between donor and accept probe is not observed.
  • the degree of hydrolysis of the peptide substrate, and the level of activity of the protease catalyzing hydrolysis of the peptide substrate can be quantitated. Accordingly, using methods known in the arts of chemical and biochemical kinetics and equilibria, the effect of inhibitor on protease activity can be quantitated.
  • compositions of the compounds of the invention alone or in combination with another NS3 protease inhibitor or another type of antiviral agent and/or another type of therapeutic agent.
  • compounds of the invention include stereoisomers, tautomers, solvates, prodrugs, pharmaceutically acceptable salts and mixtures thereof.
  • Compositions containing a compound of the invention may be prepared by conventional techniques, e.g. as described in Remington: The Science and Practice of Pharmacy, 19th Ed., 1995. The compositions may appear in conventional forms, for example capsules, tablets, aerosols, solutions, suspensions or topical applications.
  • compositions include a compound of the invention which inhibits the enzymatic activity of the HCV NS3 protease, and a pharmaceutically acceptable excipient which may be a carrier or a diluent.
  • a pharmaceutically acceptable excipient which may be a carrier or a diluent.
  • the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of an ampoule, capsule, sachet, paper, or other container.
  • the active compound When the active compound is mixed with a carrier, or when the carrier serves as a diluent, it may be solid, semi-solid, or liquid material that acts as a vehicle, excipient, or medium for the active compound.
  • the active compound can be adsorbed on a granular solid carrier, for example contained in a sachet.
  • suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, peanut oil, olive oil, gelatin, lactose, terra alba, sucrose, dextrin, magnesium carbonate, sugar, cyclodextrin, amylose, magnesium stearate, talc, gelatin, agar, pectin, acacia, stearic acid or lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, polyoxyethylene, hydroxymethylcellulose and polyvinylpyrrolidone.
  • the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate
  • the formulations can be mixed with auxiliary agents which do not deleteriously react with the active compounds.
  • auxiliary agents which do not deleteriously react with the active compounds.
  • Such additives can include wetting agents, emulsifying and suspending agents, salt for influencing osmotic pressure, buffers and/or coloring substances preserving agents, sweetening agents or flavoring agents.
  • the compositions can also be sterilized if desired.
  • the route of administration may be any route which effectively transports the active compound of the invention which inhibits the enzymatic activity of the HCV NS3 protease to the appropriate or desired site of action, such as oral, nasal, pulmonary, buccal, subdermal, intradermal, transdermal or parenteral, e.g., rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic solution or an ointment, the oral route being preferred.
  • a solid carrier is used for oral administration, the preparation may be tabletted, placed in a hard gelatin capsule in powder or pellet form or it can be in the form of a troche or lozenge.
  • a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
  • Injectable dosage forms generally include aqueous suspensions or oil suspensions which may be prepared using a suitable dispersant or wetting agent and a suspending agent Injectable forms may be in solution phase or in the form of a suspension, which is prepared with a solvent or diluent.
  • Acceptable solvents or vehicles include sterilized water, Ringer's solution, or an isotonic aqueous saline solution.
  • sterile oils may be employed as solvents or suspending agents.
  • the oil or fatty acid is non- volatile, including natural or synthetic oils, fatty acids, mono-, di- or tri-glycerides.
  • the formulation may also be a powder suitable for reconstitution with an appropriate solution as described above. Examples of these include, but are not limited to, freeze dried, rotary dried or spray dried powders, amorphous powders, granules, precipitates, or particulates.
  • the formulations may optionally contain stabilizers, pH modifiers, surfactants, bioavailability modifiers and combinations of these.
  • the compounds may be formulated for parenteral administration by injection such as by bolus injection or continuous infusion.
  • a unit dosage form for injection may be in ampoules or in multi-dose containers.
  • the formulations of the invention may be designed to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art. Thus, the formulations may also be formulated for controlled release or for slow release.
  • compositions contemplated by the present invention may comprise, for example, micelles or liposomes, or some other encapsulated form, or may be administered in an extended release form to provide a prolonged storage and/or delivery effect. Therefore, the formulations may be compressed into pellets or cylinders and implanted intramuscularly or subcutaneously as depot injections or as implants such as stents. Such implants may employ known inert materials such as silicones and biodegradable polymers, e.g., polylactide-polyglycolide. Examples of other biodegradable polymers include poly(orthoesters) and poly (anhydrides) .
  • the preparation may contain a compound of the invention which inhibits the enzymatic activity of the HCV NS3 protease, dissolved or suspended in a liquid carrier, preferably an aqueous carrier, for aerosol application.
  • a liquid carrier preferably an aqueous carrier
  • the carrier may contain additives such as solubilizing agents, e.g., propylene glycol, surfactants, absorption enhancers such as lecithin (phosphatidylcholine) or cyclodextrin, or preservatives such as parabenes.
  • injectable solutions or suspensions preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
  • Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application.
  • Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, and/or potato starch.
  • a syrup or elixir can be used in cases where a sweetened vehicle can be employed.
  • a typical tablet that may be prepared by conventional tabletting techniques may contain:
  • Active compound 250 mg Colloidal silicon dioxide (Aerosil)® 1.5 mg Cellulose, microcryst. (Avicel)® 70 mg
  • a typical capsule for oral administration contains compounds of the invention (250 mg), lactose (75 mg) and magnesium stearate (15 mg). The mixture is passed through a 60 mesh sieve and packed into a No. 1 gelatin capsule.
  • a typical injectable preparation is produced by aseptically placing 250 mg of compounds of the invention into a vial, aseptically freeze-drying and sealing. For use, the contents of the vial are mixed with 2 niL of sterile physiological saline, to produce an injectable preparation.
  • the compounds of the invention may be administered to a mammal, especially a human in need of such treatment, prevention, elimination, alleviation or amelioration of the various diseases as mentioned above, e.g.,
  • Such mammals include also animals, both domestic animals, e.g. household pets, farm animals, and non-domestic animals such as wildlife.
  • the compounds of the invention are effective over a wide dosage range.
  • dosages from about 0.5 to about 5000 mg, preferably from about 1 to about 2000 mg, and more preferably between about 2 and about 2000 mg per day may be used.
  • a typical dosage is about 10 mg to about 1000 mg per day.
  • the exact dosage will depend upon the activity of the compound, mode of administration, on the therapy desired, form in which administered, the subject to be treated and the body weight of the subject to be treated, and the preference and experience of the physician or veterinarian in charge.
  • HCV NS3 protease inhibitor activity of the compounds of the invention may be determined by use of an in vitro assay system which measures the potentiation of inhibition of the HCV NS3 protease.
  • Inhibition constants i.e., K, or IC 50 values as known in the art
  • K K, or IC 50 values as known in the art
  • the compounds of the invention are dispensed in unit dosage form comprising from about 0.5 mg to about 5000 mg of active ingredient together with a pharmaceutically acceptable carrier per unit dosage.
  • dosage forms suitable for oral, nasal, pulmonal or transdermal administration comprise from about 125 ⁇ g to about 1250 mg, preferably from about 250 ⁇ g to about 500 mg, and more preferably from about 2.5 mg to about 250 mg, of the compounds admixed with a pharmaceutically acceptable carrier or diluent.
  • the invention also encompasses prodrugs of a compound of the invention which on administration undergo chemical conversion by metabolic or other physiological processes before becoming active pharmacological substances. Conversion by metabolic or other physiological processes includes without limitation enzymatic (e.g, specific enzymatically catalyzed) and non- enzymatic (e.g., general or specific acid or base induced) chemical transformation of the prodrug into the active pharmacological substance.
  • prodrugs will be functional derivatives of a compound of the invention which are readily convertible in vivo into a compound of the invention. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in Design of Prodrugs, ed. H. Bundgaard, Elsevier, 1985.
  • compositions of a compound described herein comprising formulating a compound of the invention with a pharmaceutically acceptable carrier or diluent.
  • the pharmaceutically acceptable carrier or diluent is suitable for oral administration.
  • the methods may further comprise the step of formulating the composition into a tablet or capsule.
  • the pharmaceutically acceptable carrier or diluent is suitable for parenteral administration.
  • the methods further comprise the step of lyophilizing the composition to form a lyophilized preparation.
  • the compounds of the invention may be used in combination with i) one or more other NS3 protease inhibitors and/or ii) one or more other types of antiviral agents (employed to treat viral infection and related diseases) and/or one or more other types of therapeutic agents which may be administered orally in the same dosage form, in a separate oral dosage form (e.g., sequentially or non-sequentially) or by injection together or separately (e.g., sequentially or non- sequentially).
  • the invention provides pharmaceutical combinations, comprising: a) a compound of the invention as described herein; and b) one or more compounds comprising: i) other compounds of the present invention ii) anti-viral agents including, but not limited to, other NS3 protease inhibitors iii) antiproliferative agents iv) immune modulators.
  • Combinations of the invention include mixtures of compounds from (a) and (b) in a single formulation and compounds from (a) and (b) as separate formulations. Some combinations of the invention may be packaged as separate formulations in a kit. In some embodiments, two or more compounds from (b) are formulated together while a compound of the invention is formulated separately.
  • Combinations of the invention can further comprise a pharmaceutically acceptable carrier.
  • the compound of the invention is 90 wt % or more of a single diastereomer or single enantiomer.
  • the compound of the invention can be 91 , 92, 93, 94, 95, 96, 97, 98, or 99 wt % or more of a single diastereomer or single enantiomer.
  • the dosages and formulations for the other antiviral agent to be employed, where applicable, will be as set out in the latest edition of the Physicians' Desk Reference.
  • a composition may be employed containing the compounds of the invention, with or without another antiviral agent and/or other type therapeutic agent, in association with a pharmaceutical vehicle or diluent.
  • the composition can be formulated employing conventional solid or liquid vehicles or diluents and pharmaceutical additives of a type appropriate to the mode of desired administration.
  • the compounds can be administered to mammalian species including humans, monkeys, dogs, etc. by an oral route, for example, in the form of tablets, capsules, granules or powders, or they can be administered by a parenteral route in the form of injectable preparations.
  • the dose for adult humans is preferably between 10 and 1,000 mg per day, which can be administered in a single dose or in the form of individual doses from 1-4 times per day.
  • Compound 60 was prepared according to the procedure outlined for compound 59. Phenylsulfonamide was used in place of cyclopropylsulfonamide.
  • HCV NS3/4a of genotype Ib, 5-FAM/QXL520 fluorescence resonance energy transfer (FRET) peptide, and buffer were purchased from Anaspec, San Jose. The sequence of this FRET peptide is derived from the cleavage site of NS4a/NS4b. IC 5O/9 o calculations were performed by non-linear regression analysis using Prism software (GraphPad). Methods Biochemical assay. Either 5 ⁇ L of DMSO or 5 ⁇ L of compound solution in DMSO at various concentrations is added to 45 ⁇ L of buffer containing 5 ng of NS3/4a per well in a 96 well plates for "enzyme only" and "compound testing" wells.
  • FRET fluorescence resonance energy transfer

Abstract

La présente invention concerne de nouveaux composés qui miment des peptides avec une proline pénultième C-terminale, de tels composés étant utiles en tant qu'inhibiteurs de protéase, notamment en tant qu'inhibiteurs de sérine protéases, et plus particulièrement en tant qu'inhibiteurs de la sérine protéase NS3 du virus de l'hépatite C. Les composés trouvent une utilité en tant qu'agents antiviraux destinés à l'hépatite C. L'invention propose en outre des procédés d'utilisation de tels inhibiteurs, seuls ou en combinaison avec d'autres agents thérapeutiques, pour traiter une infection par l'hépatite C chez un sujet en besoin d'un tel traitement.
PCT/US2007/083034 2006-11-16 2007-10-30 Inhibiteurs de la sérine protéase de l'hépatite c et utilisations de ceux-ci WO2008070358A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85943306P 2006-11-16 2006-11-16
US60/859,433 2006-11-16
US88459207P 2007-01-11 2007-01-11
US60/884,592 2007-01-11

Publications (2)

Publication Number Publication Date
WO2008070358A2 true WO2008070358A2 (fr) 2008-06-12
WO2008070358A3 WO2008070358A3 (fr) 2008-11-06

Family

ID=39492946

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/083034 WO2008070358A2 (fr) 2006-11-16 2007-10-30 Inhibiteurs de la sérine protéase de l'hépatite c et utilisations de ceux-ci

Country Status (1)

Country Link
WO (1) WO2008070358A2 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010033443A1 (fr) * 2008-09-17 2010-03-25 Boehringer Ingelheim International Gmbh Polythérapie destinée à traiter une infection par le vhc
WO2011053617A1 (fr) * 2009-10-30 2011-05-05 Boehringer Ingelheim International Gmbh Régimes posologiques pour une thérapie en combinaison contre le vhc comprenant bi201335, l'interféron alpha et la ribavirine
WO2012176715A1 (fr) * 2011-06-21 2012-12-27 三菱瓦斯化学株式会社 Amide d'acide 1-amino-2-vinyl cyclopropane carboxylique, sel de celui-ci et son procédé de fabrication
CN103408559A (zh) * 2013-08-08 2013-11-27 南京大学 一种喜树碱及其衍生物的快速合成方法
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8877929B2 (en) 2008-09-04 2014-11-04 Bristol-Myers Squibb Company Process for synthesizing substituted isoquinolines
US8889871B2 (en) 2002-05-20 2014-11-18 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8993595B2 (en) 2009-04-08 2015-03-31 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9499550B2 (en) 2012-10-19 2016-11-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060926A2 (fr) * 2000-11-20 2002-08-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2003064416A1 (fr) * 2002-02-01 2003-08-07 Boehringer Ingelheim International Gmbh Tripeptides heterocycliques utiles en tant qu'inhibiteurs de l'hepatite c
WO2003099274A1 (fr) * 2002-05-20 2003-12-04 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2004101605A1 (fr) * 2003-03-05 2004-11-25 Boehringer Ingelheim International Gmbh Composes d'inhibition de l'hepatite c
WO2004103996A1 (fr) * 2003-05-21 2004-12-02 Boehringer Ingelheim International Gmbh Composes inhibiteurs de l'hepatite c
WO2005051410A1 (fr) * 2003-11-20 2005-06-09 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2006020276A2 (fr) * 2004-07-16 2006-02-23 Gilead Sciences, Inc. Composés antiviraux
WO2006086381A2 (fr) * 2005-02-08 2006-08-17 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2006122188A2 (fr) * 2005-05-10 2006-11-16 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2007008657A2 (fr) * 2005-07-11 2007-01-18 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2007015824A2 (fr) * 2005-07-25 2007-02-08 Intermune, Inc. Nouveaux inhibiteurs macrocycliques de la multiplication du virus de l’hépatite c
WO2007014919A1 (fr) * 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Inhibiteurs macrocycliques du virus de l'hépatite c
WO2007146695A1 (fr) * 2006-06-06 2007-12-21 Enanta Pharmaceuticals, Inc. Inhibiteurs oximyle acycliques de protéase de l'hépatite c
WO2008005511A2 (fr) * 2006-07-05 2008-01-10 Intermune, Inc. Nouveaux inhibiteurs de la réplication du virus de l'hépatite c
WO2008008776A2 (fr) * 2006-07-11 2008-01-17 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
WO2008021956A2 (fr) * 2006-08-11 2008-02-21 Enanta Pharmaceuticals, Inc. Inhibiteurs d'acylamino-hétéroaryle de la protéase du virus de l'hépatite c

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060926A2 (fr) * 2000-11-20 2002-08-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2003064416A1 (fr) * 2002-02-01 2003-08-07 Boehringer Ingelheim International Gmbh Tripeptides heterocycliques utiles en tant qu'inhibiteurs de l'hepatite c
WO2003099274A1 (fr) * 2002-05-20 2003-12-04 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2004101605A1 (fr) * 2003-03-05 2004-11-25 Boehringer Ingelheim International Gmbh Composes d'inhibition de l'hepatite c
WO2004103996A1 (fr) * 2003-05-21 2004-12-02 Boehringer Ingelheim International Gmbh Composes inhibiteurs de l'hepatite c
WO2005051410A1 (fr) * 2003-11-20 2005-06-09 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2006020276A2 (fr) * 2004-07-16 2006-02-23 Gilead Sciences, Inc. Composés antiviraux
WO2006086381A2 (fr) * 2005-02-08 2006-08-17 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2006122188A2 (fr) * 2005-05-10 2006-11-16 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2007008657A2 (fr) * 2005-07-11 2007-01-18 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2007015824A2 (fr) * 2005-07-25 2007-02-08 Intermune, Inc. Nouveaux inhibiteurs macrocycliques de la multiplication du virus de l’hépatite c
WO2007014919A1 (fr) * 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Inhibiteurs macrocycliques du virus de l'hépatite c
WO2007146695A1 (fr) * 2006-06-06 2007-12-21 Enanta Pharmaceuticals, Inc. Inhibiteurs oximyle acycliques de protéase de l'hépatite c
WO2008005511A2 (fr) * 2006-07-05 2008-01-10 Intermune, Inc. Nouveaux inhibiteurs de la réplication du virus de l'hépatite c
WO2008008776A2 (fr) * 2006-07-11 2008-01-17 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
WO2008021956A2 (fr) * 2006-08-11 2008-02-21 Enanta Pharmaceuticals, Inc. Inhibiteurs d'acylamino-hétéroaryle de la protéase du virus de l'hépatite c

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9636375B2 (en) 2002-05-20 2017-05-02 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9227940B2 (en) 2002-05-20 2016-01-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8889871B2 (en) 2002-05-20 2014-11-18 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8877929B2 (en) 2008-09-04 2014-11-04 Bristol-Myers Squibb Company Process for synthesizing substituted isoquinolines
US8399484B2 (en) 2008-09-17 2013-03-19 Boehringer Ingelheim International Gmbh Combination therapy for treating HCV infection
WO2010033443A1 (fr) * 2008-09-17 2010-03-25 Boehringer Ingelheim International Gmbh Polythérapie destinée à traiter une infection par le vhc
EA019965B1 (ru) * 2008-09-17 2014-07-30 Бёрингер Ингельхайм Интернациональ Гмбх Комбинация ингибитора протеазы ns3 hcv с интерфероном и рибавирином
AU2009293493B2 (en) * 2008-09-17 2014-09-18 Boehringer Ingelheim International Gmbh Combination of HCV NS3 protease inhibitor with interferon and ribavirin
US8993595B2 (en) 2009-04-08 2015-03-31 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
US8822496B2 (en) 2009-10-30 2014-09-02 Boehringer Ingelheim International Gmbh Dosage regimens for HCV combination therapy
AU2010313497B2 (en) * 2009-10-30 2013-08-01 Boehringer Ingelheim International Gmbh Dosage regimens for HCV combination therapy comprising BI201335, interferon alpha and ribavirin
WO2011053617A1 (fr) * 2009-10-30 2011-05-05 Boehringer Ingelheim International Gmbh Régimes posologiques pour une thérapie en combinaison contre le vhc comprenant bi201335, l'interféron alpha et la ribavirine
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9527885B2 (en) 2011-05-05 2016-12-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012176715A1 (fr) * 2011-06-21 2012-12-27 三菱瓦斯化学株式会社 Amide d'acide 1-amino-2-vinyl cyclopropane carboxylique, sel de celui-ci et son procédé de fabrication
US9499550B2 (en) 2012-10-19 2016-11-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN103408559B (zh) * 2013-08-08 2016-06-29 南京大学 一种喜树碱及其衍生物的快速合成方法
CN103408559A (zh) * 2013-08-08 2013-11-27 南京大学 一种喜树碱及其衍生物的快速合成方法

Also Published As

Publication number Publication date
WO2008070358A3 (fr) 2008-11-06

Similar Documents

Publication Publication Date Title
WO2008070358A2 (fr) Inhibiteurs de la sérine protéase de l'hépatite c et utilisations de ceux-ci
US20100323953A1 (en) Macrocyclic hepatitis c protease inhibitors
US20090304631A1 (en) Hepatitis c serine protease inhibitors and uses therefor
US20100120716A1 (en) Macrocyclic hepatitis c serine protease inhibitors and uses therefor
US20090325889A1 (en) Hepatitis c serine protease inhibitors and uses therefor
WO2010033466A1 (fr) Inhibiteurs macrocycliques de la protéase du virus de l'hépatite c
JP5932929B2 (ja) Ｃ型肝炎ウイルス複製の阻害剤
JP5419468B2 (ja) Ｉａｐのｂｉｒドメインに結合する化合物
EP2041156B1 (fr) 4-amino-4-oxobutanoyl peptides en tant qu'inhibiteurs de la réplication virale
EP2219453B1 (fr) Composes contenant de la quinoxaline en tant qu'inhibiteurs du virus de l'hepatite c
AU2010257200B2 (en) Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease
CN104829688B (zh) 大环脯氨酸衍生的hcv丝氨酸蛋白酶抑制剂
RU2401840C2 (ru) Ингибиторы iap
EP1613620A1 (fr) Inhibiteurs des serine proteases, en particulier de la protease ns3-ns4a du vhc
JP2011506329A (ja) キノキサリニル誘導体
CA2538791A1 (fr) Inhibiteurs de serines proteases, en particulier de la protease ns3-ns4a du vhc
KR20120140658A (ko) Ｉａｐ ｂｉｒ 도메인 결합 화합물
BRPI0714074A2 (pt) inibidores de serina protease de vìrus de hepatite c macrocìclico quinoxalinila
CN101857631A (zh) 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
KR20100020484A (ko) 헤테로아릴 치환된 티아졸 그리고 항-바이러스제로서의 그들의 사용
WO2009102876A1 (fr) Inhibiteurs macrocycliques de protéase de l'hépatite c
CN1906208B (zh) 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
KR20140000689A (ko) 술파미드 ｎｓ3 억제제의 염 및 다형체

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07871294

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07871294

Country of ref document: EP

Kind code of ref document: A2